ALBRIOZA Commercial Launch

Progressive Supranuclear Palsy (PSP) Selected as Next Indication for AMX0035 Clear unmet need Typically fatal within just 5 to 8 years; no disease-modifying treatments for PSP Strong scientific rationale PSP leads to rapid & significant neurodegeneration and is characterized by tau protein deposition in affected regions of brain; AMX0035 shown preclinically to protect neurons against degeneration and clinically to lower tau Biomarker evidence AMX0035 demonstrated a statistically significant lowering of phosphotau181 & total tau in the CSF of people with Alzheimer's disease Existing and robust understanding of the natural history of the disease PSP progression is predictable and well understood Potential to move directly into a Phase 3 pivotal trial Preparing for Phase 3 study with ~600 adults in a randomized, placebo-controlled study Adjacencies and synergies with ALS Shares mechanistic characteristics with ALS - unfolded protein response, mitochondrial dysfunction and related cell death Interest and support from KOLS and advocacy groups Collaborated with key global academic leaders, people living with PSP, and advocacy groups AMYLYX 29

View entire presentation